Actively Recruiting
Effect of Quinine Hydrochloride in Overweight Population on Food Intake, Hunger and Gut Peptide Release
Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2024-07-03
40
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The worldwide increase in the prevalence of obesity is a cause of great concern. Pharmacological treatment options are being explored at the moment with a major focus on the hormones produced by the gastrointestinal tract which regulate hunger and satiation/satiety. Modulating the release of these hormones via bitter substances reduced appetite-related sensations and gastrointestinal motility in lean female volunteers. Intragastric administration of a quinine-solution has shown to decrease hunger sensations in healthy female volunteers. Now, we want to examine whether this effect is still seen in an overweight female population.
CONDITIONS
Official Title
Effect of Quinine Hydrochloride in Overweight Population on Food Intake, Hunger and Gut Peptide Release
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female aged between 18 and 65 years
- BMI between 25 and 30 kg/m² with stable body weight for at least 3 months before the study and during the study visits
- Women of child-bearing age agree to use a highly effective birth control method throughout the trial or are surgically sterile or postmenopausal for at least 2 years without spontaneous menses
- Understands study procedures and provides written informed consent
You will not qualify if you...
- Male, under legal age of consent, pregnant, or breastfeeding
- BMI less than or equal to 25 kg/m² or greater than or equal to 30 kg/m²
- Current symptoms or history of gastrointestinal, significant somatic or psychiatric diseases, or drug allergies
- Currently following a weight loss diet or other obesity treatment
- Diagnosis of diabetes
- Significant heart, lung, liver, or kidney disease
- QT-interval greater than 450 ms
- History of neurological disorders
- History of abdominal surgery except simple appendectomy over 1 year ago
- Retinopathy
- Psoriasis
- Porphyria
- Hematologic disorders such as hemolysis or thrombocytopenia
- Abnormal eating behavior or history of eating disorder
- Use of drugs affecting blood sugar, gastrointestinal function, motility, sensitivity, or gastric acidity
- Use of centrally acting medications including antidepressants, antipsychotics, or benzodiazepines within the past year
- Excessive alcohol consumption (more than 14 units per week)
- Regular or irregular use of illicit drugs within approximately 1 year or unwillingness to refrain from drug use during the study
- High caffeine intake (more than 4 cups of coffee daily or equivalent)
- Inability or unwillingness to complete all study procedures or deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
TARGID
Leuven, Vlaams-Brabant, Belgium, 3000
Actively Recruiting
Research Team
W
Wout Verbeure
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here